AgomAb Therapeutics N.V. American Depositary Shares AGMB · SEC Filings

website

AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel...

Price7.55

Market Cap371.82 M

Float36.45 M

CountryBE

SectorHealthcare

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

Financials

TYPE

HEADLINE

FILED AT

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Apr 23, 2026

News

TYPE

HEADLINE

FILED AT

6-K

Agomab Doses First Patient in Global NOV-ERA Phase 2b Study of Ontunisertib for Fibrostenosing Crohn’s Disease

Oct 13, 2026

6-K

Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn’s Disease

Oct 1, 2026

6-K

Agomab Announces Positive Phase 1 Results for AGMB-447 in Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study

Sep 14, 2026

6-K

Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors

Sep 11, 2026

6-K

Agomab Therapeutics Announces Proposed Board Appointments and Upcoming Shareholder Meetings

Aug 10, 2026

6-K

Agomab Therapeutics Reports Half Year 2026 Financial Results and Confirms 2026 Clinical Outlook

Aug 6, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B4

IPO | Offering amount: $200,000,000 | Shares: 12,500,000 | Price: $16.000 | Bank: J.P. Morgan, Morgan Stanley, Leerink Partners, Van Lanschot Kempen

Feb 6, 2026

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 11, 2026

8-A12B

Form 8-A12B - Registration of securities [Section 12(b)]

Feb 3, 2026

F-1/A

OFFERING | Bank: J.P. Morgan, Morgan Stanley, Leerink Partners, Van Lanschot Kempen

Jan 29, 2026

F-1

OFFERING | Bank: J.P. Morgan

Jan 16, 2026

DRS/A

Form DRS/A - Draft Registration Statement: [Amend]

Dec 17, 2025

DRS/A

Form DRS/A - Draft Registration Statement: [Amend]

Oct 27, 2025

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

Epstein David R (Reporting)

Nov 6, 2026

Epstein David R (Reporting)

Oct 22, 2026

Epstein David R (Reporting)

Oct 9, 2026

Epstein David R (Reporting)

Oct 7, 2026

Kemula Pierre Thadee Victor (Reporting)

Oct 7, 2026

Knotnerus Tim Jasper (Reporting)

Oct 7, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Feb 2, 2026